BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/23/2022 9:44:44 AM | Browse: 757 | Download: 1981
Publication Name World Journal of Clinical Cases
Manuscript ID 78831
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac & Cardiovascular Systems
Manuscript Type Randomized Controlled Trial
Article Title Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial
Manuscript Source Unsolicited Manuscript
All Author List Yi-Jing Zhang, Lin Yin and Jun Li
ORCID
Author(s) ORCID Number
Yi-Jing Zhang http://orcid.org/0000-0001-9314-1774
Lin Yin http://orcid.org/0000-0002-6244-7241
Jun Li http://orcid.org/0000-0002-5577-8720
Funding Agency and Grant Number
Corresponding Author Jun Li, BSc, Chief Nurse, Department of Imaging, 904th Hospital of Joint Logistic Support Force of PLA, No. 101 Xing Yuan North Road, Wuxi 214044, Jiangsu Province, China. sm2008@21cn.com
Key Words Natriuretic peptide; Myocardial infarction; Contrast media; Acute myocardial infarction; Percutaneous coronary intervention
Core Tip Increasing evidence indicates that emergency percutaneous coronary intervention (PCI) is the most effective method for the treatment of acute myocardial infarction (AMI). However, with the increase of emergency PCI, contrast-induced nephropathy (CIN) is becoming more and more common, which also leads to the increase of the proportion of patients with renal dysfunction, aggravating the cost of hospitalization and prolonging the length of hospital stay. CIN cannot be managed or prevented with current medications. Recombinant human B-type natriuretic peptide (rhBNP) is the natriuretic peptide receptor A, and increasing reports have demonstrated that rhBNP can improve AMI and heart failure. However, whether it can improve renal function and decrease the risk of CIN in elderly patients is still unclear. In this study, we explored the effectiveness of rhBNP treatment in postoperative CIN in elderly AMI patients. We found that early application of rhBNP after primary PCI could protect renal function, reduce serum creatinine and cystatin C levels, improve creatinine clearance rate, and decrease the risk of CIN and acute heart failure in AMI patients. We showed rhBNP as an effective drug to prevent CIN in the elderly after PCI.
Publish Date 2022-11-23 09:44
Citation Zhang YJ, Yin L, Li J. Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial. World J Clin Cases 2022; 10(33): 12221-12229
URL https://www.wjgnet.com/2307-8960/full/v10/i33/12221.htm
DOI https://dx.doi.org/10.12998/wjcc.v10.i33.12221
Full Article (PDF) WJCC-10-12221.pdf
Full Article (Word) WJCC-10-12221.docx